| 证券代码：300298 | 证券简称：三诺生物 | 公告编号：2024-041 | | --- | --- | --- | | 债券代码：123090 | 债券简称：三诺转债 | | 三诺生物传感股份有限公司 关于召开2023年年度股东大会的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 3、会议召开的合法、合规性：本次股东大会的召集、召开符合有关法律法 规、深圳证券交易所业务规则和《公司章程》的规定。 假记载、误导性陈述或重大遗漏。 三诺生物传感股份有限公司（以下简称"公司"）于 2024 年 4 月 26 日在巨 潮资讯网（www.cninfo.com.cn）上刊登了《关于召开 2023 年年度股东大会的通 知》（公告编号：2024-035），公司将于 2024 年 5 月 21 日（星期二）下午 14:30 召开 2023 年年度股东大会，本次股东大会采用现场投票与网络投票相结合的方 式召开。现将会议有关事项提示如下： 一、召开会议的基本情况 1、股东大会届次：2023 年年度股东大会 （1）现场会议召开日期、时间：2024 年 5 月 21 日（星期二）下午 14:3 ...

中信证券股份有限公司 关于三诺生物传感股份有限公司 | （2）列席公司董事会次数 | 0次 | | --- | --- | | （3）列席公司监事会次数 | 0次 | | 5.现场检查情况 | | | （1）现场检查次数 | 2次 | | （2）现场检查报告是否按照深圳证券交易所规定 | 是 | | 报送 | | | （3）现场检查发现的主要问题及整改情况 | 无 | | 6.发表专项意见情况 | | | （1）发表专项意见次数 | 6次 | | （2）发表非同意意见所涉问题及结论意见 | 无 | | 7.向深圳证券交易所报告情况（现场检查报告除 | | | 外） | | | （1）向深圳证券交易所报告的次数 | 无 | | （2）报告事项的主要内容 | 不适用 | | （3）报告事项的进展或者整改情况 | 不适用 | | 8.关注职责的履行情况 | | | （1）是否存在需要关注的事项 | 不适用 | | （2）关注事项的主要内容 | 不适用 | | （3）关注事项的进展或者整改情况 | 不适用 | | 9.保荐业务工作底稿记录、保管是否合规 | 是 | | 10.对上市公司培训情况 | | | （1）培训 ...

2023 年度持续督导定期现场检查报告 | 保荐人名称：中信证券股份有限公司 被保荐公司简称：三诺生物传感股份有 | | --- | | （以下简称"中信证券"或"保荐人"） 限公司 | | 保荐代表人姓名：邵才捷 联系电话：021- 2026 2067 | | 保荐代表人姓名：王栋 联系电话：010- 6083 3110 | | 现场检查人员姓名：邵才捷 | | 年 月 年 月 日 现场检查对应期间：2023 1 1 日-2023 12 31 | | 现场检查时间：2024 年 月 日至 年 月 日、2024 年 月 日 4 16 2024 4 17 4 28 | | 一、现场检查事项 现场检查意见 | | （一）公司治理 是 否 不适用 | | 现场检查手段： | | 1、对上市公司董事、监事、高级管理人员及有关人员进行持续督导培训； | | 2、查看上市公司的主要生产、经营、管理场所； | | 3、对有关文件进行查阅。 | | 现场检查手段： | | 查阅了上市公司最新章程、三会议事规则及会议材料，取得上市公司董事、监事、 | | 高级管理人员名单及其变化情况，取得上市公司关联方清单，查阅关于公司控股 ...

医药生物/医疗器械 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | |----------------------------------|--------------|--------------|--------------------------|--------------|--------------|------------------------------|--------------|--------------|--------------|----------------------|------------| | | | | | | | | | | | | | | 资产负债表 ( 百万元 ) 流动资产 | 2022A 2375 | 2023A 2106 | 2024E 2970 | 2025E 2932 | 2026E 3894 | 利润表 ( 百万元 ) 营业收入 | 2022A 3952 | 2023A 4059 | 2024E 4981 | 2025E 5794 | 2026E 6 ...

Investment Rating - The investment rating for Sanofi Biologicals (300298) is to "Maintain Attention" [24][36]. Core Views - The report highlights the steady growth of the domestic blood glucose meter market, driven by increasing diabetes prevalence and patient awareness. The company is expected to strengthen its market leadership in both hospital and outpatient settings [4]. - The report anticipates a sales growth of 12% for blood glucose meters in both domestic and international markets from 2024 to 2026, with specific growth rates of 15%, 14%, and 13% for domestic sales and 5%, 5%, and 4% for international sales [4][6]. - The company achieved a revenue of 4.06 billion yuan in 2023, a 2.7% increase, while the net profit attributable to shareholders decreased by 36.3% to 280 million yuan. The first quarter of 2024 saw a revenue increase of 14.9% to 1.01 billion yuan, with a net profit increase of 35.5% [16][25]. Summary by Sections Financial Performance - In 2023, the company reported a total revenue of 4.06 billion yuan, with a net profit of 280 million yuan, reflecting a decrease of 36.3%. The first quarter of 2024 showed a revenue of 1.01 billion yuan, up 14.9%, and a net profit of 80 million yuan, up 35.5% [16][25]. - The gross margin for 2023 was 54.1%, which decreased to 50.7% in the first quarter of 2024 due to production ramp-up and the impact of THI's consolidation [16][25]. Market Position and Growth - The company is expanding its Continuous Glucose Monitoring (CGM) product line, which achieved over 100 million yuan in sales in 2023. The CGM products are receiving positive feedback, and the company is actively pursuing international certifications [16][25]. - The report indicates that the company has established a presence in over 3,500 hospitals and has over 22 million users, with a retail market share of nearly 50% [16][25]. Future Projections - The forecast for net profit attributable to shareholders is 430 million yuan in 2024, 510 million yuan in 2025, and 680 million yuan in 2026, with corresponding PE ratios of 32, 27, and 20 [16][25]. - The report suggests that the company will continue to enhance its market share through product strength and global market expansion, particularly in the CGM segment [16][25].

Investment Rating - The investment rating for the company is "Hold" with a target price not specified for the next 6 months [20][46]. Core Views - The company reported a revenue of 4.06 billion yuan in 2023, with a year-on-year growth of 44.26%. The net profit attributable to the parent company was 284.40 million yuan, down 36.31% from the previous year [32][38]. - The Continuous Glucose Monitoring (CGM) segment is experiencing rapid growth, with sales exceeding 1 billion yuan in 2023. The company is actively pursuing international certifications and expanding its global market presence [32][34]. - The Blood Glucose Monitoring (BGM) segment showed stable growth, with a revenue increase of 10.1% in 2023, supported by extensive market coverage and partnerships [32][34]. - The company is increasing its R&D investments, which is expected to enhance gross margins in the future [32][34]. Financial Summary - Revenue projections for 2024, 2025, and 2026 are 4.85 billion yuan, 5.71 billion yuan, and 6.69 billion yuan, respectively, with growth rates of 19.50%, 17.70%, and 17.20% [35][38]. - The net profit forecast for 2024, 2025, and 2026 is 433.24 million yuan, 505.10 million yuan, and 677.78 million yuan, corresponding to growth rates of 52.34%, 16.59%, and 34.19% [35][38]. - The company's PE ratios for the next three years are projected to be 32, 27, and 20, indicating a decreasing trend [35][38]. Market Position and Competitiveness - The company has a significant market presence, covering over 3,500 hospitals and collaborating with more than 4,000 distributors and nearly 600 chain pharmacies [32][34]. - The CGM product "Sanofi Aikan" has received multiple certifications across various regions, enhancing its competitive edge in the market [32][34]. - The company is expected to gradually improve its domestic market share and expand its global footprint through product strength and strategic initiatives [32][34].

Investment Rating - The report assigns an "Accumulate" rating for the company, indicating an expected investment return that exceeds the market benchmark index by 5% to 15% over the next 6-12 months [23][22]. Core Insights - The company's revenue for 2023 reached 4.058 billion yuan, reflecting a year-on-year growth of 2.69%, while the net profit attributable to shareholders decreased by 36.31% to 284.4 million yuan [20][3]. - The traditional domestic business has shown resilience in revenue growth despite challenges, but net profit has declined due to increased R&D and market investments in the Continuous Glucose Monitoring (CGM) system, as well as operational losses and goodwill impairment from its U.S. subsidiary [4][10]. - The CGM market is projected to grow significantly, with the company expected to benefit from this trend, potentially opening a second growth curve [11][21]. Financial Performance Summary - In 2023, the company reported a gross margin of 54.06%, down 4.65 percentage points from the previous year, and a net margin of 4.83%, a decrease of 10.39 percentage points year-on-year [4]. - The company’s R&D expenditure was 356 million yuan, a 16.36% increase from the previous year, accounting for 8.78% of total revenue [4]. - Revenue projections for 2024, 2025, and 2026 are estimated at 45.80 billion yuan, 51.67 billion yuan, and 59.19 billion yuan, respectively, with corresponding net profits of 466 million yuan, 543 million yuan, and 641 million yuan [22]. Market Position and Growth Potential - The CGM system's market share is expected to grow from less than 30% in 2020 to 49.4% by 2030, with the market size expanding from 1.7 billion USD in 2015 to an anticipated 36.5 billion USD by 2030 [11][20]. - The company has successfully registered its CGM products in seven global regions and launched them domestically, positioning itself well for future growth [11][20].

| 证券代码：300298 | 证券简称：三诺生物 | 公告编号：2024-040 | | --- | --- | --- | | 债券代码：123090 | 债券简称：三诺转债 | | 三诺生物传感股份有限公司 关于控股股东部分股份质押及解除质押的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 三诺生物传感股份有限公司（以下简称"公司"）于近日接到公司控股股东、 实际控制人李少波先生的通知，获悉其所持有本公司的部分股份办理了新的质押 业务，原已质押的部分股份办理了解除质押业务，现将有关情况说明如下： | 李少波 | | 是 | 5,500,000 | 3.85% | 0.97% | 2021 年 5 月 25 日 | 2024 年 5 月 10 日 | 国泰君安证券股份有限公司 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 李少波 | | 是 | 2,300,000 | 1.61% | 0.41% | 2022 年 4 月 12 日 | 2024 年 5 月 10 日 | 国泰君 ...

证 券 研 究 报 告 医药生物 ——2023 年受海外子公司拖累，2024Q1 超预期 | --- | --- | |---------------------------------|-------------------------------| | | | | | | | 基础数据 : | 2024 年 03 月 31 日 | | 每股净资产（元） | 5.51 | | 资产负债率 % | 39.66 | | 总股本/ 流通 A 股（百万） | 564/455 | | 流通 B 股/H 股（百万） | -/- | 05-0406-0407-0408-0409-0410-0411-0412-0401-0402-0403-0404-04 -40% -20% 0% 20% 三诺生物 沪深300指数（收益率） 《三诺生物（300298）点评：短期受子公 司 拖 累 ， 看 好 公 司 第 二 成 长 曲 线 》 2024/01/29 《三诺生物（300298）点评：业绩符合预 期，公司 CGM 稳步推进》 2023/10/25 陈烨远 A0230521050001 chenyy@swsresearch.com ...

三诺生物传感股份有限公司 关于回购公司部分股份的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 | 证券代码：300298 | 证券简称：三诺生物 | 公告编号：2024-039 | | --- | --- | --- | | 债券代码：123090 | 债券简称：三诺转债 | | 1、公司未在下列期间内回购公司股份： （1）自可能对本公司证券及其衍生品种交易价格产生重大影响的重大事项 发生之日或者在决策过程中，至依法披露之日内； （2）中国证监会规定和深圳证券交易所规定的其他情形。 假记载、误导性陈述或重大遗漏。 三诺生物传感股份有限公司（以下简称"公司"）于 2023 年 8 月 7 日召开第 五届董事会第四次会议和第五届监事会第四次会议，审议并通过《关于回购公司 部分股份方案的议案》，独立董事就本次回购事项发表了同意的独立意见，同意 公司使用自有资金不低于人民币 8,000 万元且不超过人民币 15,000 万元（均含本 数），以集中竞价交易的方式回购公司部分社会公众股份，用于员工持股计划或 者股权激励。回购价格不超过人民币 35.00 元/股（含），实施期限自董事会审议 通 ...